Exomics and immunogenics
Stéphane Champiat, Charles Ferté, Sophie Lebel‐Binay et al. · OncoImmunology · 2014
Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tumors that bear high level of somatic mutations, like melanoma or non-small cell lung carcinoma. We herein formulate the hypothesis that high levels of mutational heterogeneity in the tumor could be the key for the success of immune checkpoint-targeting therapies.
Cited by 192 works. doi:10.4161/onci.27817
Authors
References
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- The blockade of immune checkpoints in cancer immunotherapy
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Signatures of mutational processes in human cancer
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- Cancer Genome Landscapes
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- A small-cell lung cancer genome with complex signatures of tobacco exposure
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma